Analgesics
Antiandrogens
Antihistamines
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
PPIs
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
 
next
study
previous
study
c19early.org COVID-19 treatment researchQuercetinQuercetin (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis       

Structure-based virtual identification of natural inhibitors of SARS-CoV-2 and its Delta and Omicron variant proteins

Alanzi et al., Future Virology, doi:10.2217/fvl-2022-0184
Jun 2023  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Quercetin for COVID-19
24th treatment shown to reduce risk in July 2021, now with p = 0.002 from 12 studies.
No treatment is 100% effective. Protocols combine treatments.
5,100+ studies for 112 treatments. c19early.org
In Silico study showing the flavonoid quercetin and its derivative quercetin-3-acetyl-glucoside exhibit potential inhibitory activity against SARS-CoV-2 main protease, helicase, and spike proteins. Related flavonoids like rutin and kaempferol also demonstrated strong predicted binding.
73 preclinical studies support the efficacy of quercetin for COVID-19:
In Silico studies predict inhibition of SARS-CoV-2, or minimization of side effects, with quercetin or metabolites via binding to the spikeA,3,9,10,22,24,25,30,38,39,41,42,62-64, MproB,3,7,9,11,13,15,17,18,20,23,24,30,34,36-38,42,43,45,63-65, RNA-dependent RNA polymeraseC,1,3,9,32,64, PLproD,3,37,45, ACE2E,22,23,28,37,41,63, TMPRSS2F,22, nucleocapsidG,3, helicaseH,3,29,34, endoribonucleaseI,39, NSP16/10J,6, cathepsin LK,26, Wnt-3L,22, FZDM,22, LRP6N,22, ezrinO,40, ADRPP,38, NRP1Q,41, EP300R,16, PTGS2S,23, HSP90AA1T,16,23, matrix metalloproteinase 9U,31, IL-6V,21,35, IL-10W,21, VEGFAX,35, and RELAY,35 proteins. In Vitro studies demonstrate inhibition of the MproB,15,46,51,59 protein, and inhibition of spike-ACE2 interactionZ,47. In Vitro studies demonstrate efficacy in Calu-3AA,50, A549AB,21, HEK293-ACE2+AC,58, Huh-7AD,25, Caco-2AE,49, Vero E6AF,19,42,49, mTECAG,52, and RAW264.7AH,52 cells. Animal studies demonstrate efficacy in K18-hACE2 miceAI,55, db/db miceAJ,52,61, BALB/c miceAK,60, and rats66. Quercetin reduced proinflammatory cytokines and protected lung and kidney tissue against LPS-induced damage in mice60, inhibits LPS-induced cytokine storm by modulating key inflammatory and antioxidant pathways in macrophages5, and inhibits SARS-CoV-2 ORF3a ion channel activity, which contributes to viral pathogenicity and cytotoxicity54.
a. The trimeric spike (S) protein is a glycoprotein that mediates viral entry by binding to the host ACE2 receptor, is critical for SARS-CoV-2's ability to infect host cells, and is a target of neutralizing antibodies. Inhibition of the spike protein prevents viral attachment, halting infection at the earliest stage.
b. The main protease or Mpro, also known as 3CLpro or nsp5, is a cysteine protease that cleaves viral polyproteins into functional units needed for replication. Inhibiting Mpro disrupts the SARS-CoV-2 lifecycle within the host cell, preventing the creation of new copies.
c. RNA-dependent RNA polymerase (RdRp), also called nsp12, is the core enzyme of the viral replicase-transcriptase complex that copies the positive-sense viral RNA genome into negative-sense templates for progeny RNA synthesis. Inhibiting RdRp blocks viral genome replication and transcription.
d. The papain-like protease (PLpro) has multiple functions including cleaving viral polyproteins and suppressing the host immune response by deubiquitination and deISGylation of host proteins. Inhibiting PLpro may block viral replication and help restore normal immune responses.
e. The angiotensin converting enzyme 2 (ACE2) protein is a host cell transmembrane protein that serves as the cellular receptor for the SARS-CoV-2 spike protein. ACE2 is expressed on many cell types, including epithelial cells in the lungs, and allows the virus to enter and infect host cells. Inhibition may affect ACE2's physiological function in blood pressure control.
f. Transmembrane protease serine 2 (TMPRSS2) is a host cell protease that primes the spike protein, facilitating cellular entry. TMPRSS2 activity helps enable cleavage of the spike protein required for membrane fusion and virus entry. Inhibition may especially protect respiratory epithelial cells, buy may have physiological effects.
g. The nucleocapsid (N) protein binds and encapsulates the viral genome by coating the viral RNA. N enables formation and release of infectious virions and plays additional roles in viral replication and pathogenesis. N is also an immunodominant antigen used in diagnostic assays.
h. The helicase, or nsp13, protein unwinds the double-stranded viral RNA, a crucial step in replication and transcription. Inhibition may prevent viral genome replication and the creation of new virus components.
i. The endoribonuclease, also known as NendoU or nsp15, cleaves specific sequences in viral RNA which may help the virus evade detection by the host immune system. Inhibition may hinder the virus's ability to mask itself from the immune system, facilitating a stronger immune response.
j. The NSP16/10 complex consists of non-structural proteins 16 and 10, forming a 2'-O-methyltransferase that modifies the viral RNA cap structure. This modification helps the virus evade host immune detection by mimicking host mRNA, making NSP16/10 a promising antiviral target.
k. Cathepsin L is a host lysosomal cysteine protease that can prime the spike protein through an alternative pathway when TMPRSS2 is unavailable. Dual targeting of cathepsin L and TMPRSS2 may maximize disruption of alternative pathways for virus entry.
l. Wingless-related integration site (Wnt) ligand 3 is a host signaling molecule that activates the Wnt signaling pathway, which is important in development, cell growth, and tissue repair. Some studies suggest that SARS-CoV-2 infection may interfere with the Wnt signaling pathway, and that Wnt3a is involved in SARS-CoV-2 entry.
m. The frizzled (FZD) receptor is a host transmembrane receptor that binds Wnt ligands, initiating the Wnt signaling cascade. FZD serves as a co-receptor, along with ACE2, in some proposed mechanisms of SARS-CoV-2 infection. The virus may take advantage of this pathway as an alternative entry route.
n. Low-density lipoprotein receptor-related protein 6 is a cell surface co-receptor essential for Wnt signaling. LRP6 acts in tandem with FZD for signal transduction and has been discussed as a potential co-receptor for SARS-CoV-2 entry.
o. The ezrin protein links the cell membrane to the cytoskeleton (the cell's internal support structure) and plays a role in cell shape, movement, adhesion, and signaling. Drugs that occupy the same spot on ezrin where the viral spike protein would bind may hindering viral attachment, and drug binding could further stabilize ezrin, strengthening its potential natural capacity to impede viral fusion and entry.
p. The Adipocyte Differentiation-Related Protein (ADRP, also known as Perilipin 2 or PLIN2) is a lipid droplet protein regulating the storage and breakdown of fats in cells. SARS-CoV-2 may hijack the lipid handling machinery of host cells and ADRP may play a role in this process. Disrupting ADRP's interaction with the virus may hinder the virus's ability to use lipids for replication and assembly.
q. Neuropilin-1 (NRP1) is a cell surface receptor with roles in blood vessel development, nerve cell guidance, and immune responses. NRP1 may function as a co-receptor for SARS-CoV-2, facilitating viral entry into cells. Blocking NRP1 may disrupt an alternative route of viral entry.
r. EP300 (E1A Binding Protein P300) is a transcriptional coactivator involved in several cellular processes, including growth, differentiation, and apoptosis, through its acetyltransferase activity that modifies histones and non-histone proteins. EP300 facilitates viral entry into cells and upregulates inflammatory cytokine production.
s. Prostaglandin G/H synthase 2 (PTGS2, also known as COX-2) is an enzyme crucial for the production of inflammatory molecules called prostaglandins. PTGS2 plays a role in the inflammatory response that can become severe in COVID-19 and inhibitors (like some NSAIDs) may have benefits in dampening harmful inflammation, but note that prostaglandins have diverse physiological functions.
t. Heat Shock Protein 90 Alpha Family Class A Member 1 (HSP90AA1) is a chaperone protein that helps other proteins fold correctly and maintains their stability. HSP90AA1 plays roles in cell signaling, survival, and immune responses. HSP90AA1 may interact with numerous viral proteins, but note that it has diverse physiological functions.
u. Matrix metalloproteinase 9 (MMP9), also called gelatinase B, is a zinc-dependent enzyme that breaks down collagen and other components of the extracellular matrix. MMP9 levels increase in severe COVID-19. Overactive MMP9 can damage lung tissue and worsen inflammation. Inhibition of MMP9 may prevent excessive tissue damage and help regulate the inflammatory response.
v. The interleukin-6 (IL-6) pro-inflammatory cytokine (signaling molecule) has a complex role in the immune response and may trigger and perpetuate inflammation. Elevated IL-6 levels are associated with severe COVID-19 cases and cytokine storm. Anti-IL-6 therapies may be beneficial in reducing excessive inflammation in severe COVID-19 cases.
w. The interleukin-10 (IL-10) anti-inflammatory cytokine helps regulate and dampen immune responses, preventing excessive inflammation. IL-10 levels can also be elevated in severe COVID-19. IL-10 could either help control harmful inflammation or potentially contribute to immune suppression.
x. Vascular Endothelial Growth Factor A (VEGFA) promotes the growth of new blood vessels (angiogenesis) and has roles in inflammation and immune responses. VEGFA may contribute to blood vessel leakiness and excessive inflammation associated with severe COVID-19.
y. RELA is a transcription factor subunit of NF-kB and is a key regulator of inflammation, driving pro-inflammatory gene expression. SARS-CoV-2 may hijack and modulate NF-kB pathways.
z. The interaction between the SARS-CoV-2 spike protein and the human ACE2 receptor is a primary method of viral entry, inhibiting this interaction can prevent the virus from attaching to and entering host cells, halting infection at an early stage.
aa. Calu-3 is a human lung adenocarcinoma cell line with moderate ACE2 and TMPRSS2 expression and SARS-CoV-2 susceptibility. It provides a model of the human respiratory epithelium, but many not be ideal for modeling early stages of infection due to the moderate expression levels of ACE2 and TMPRSS2.
ab. A549 is a human lung carcinoma cell line with low ACE2 expression and SARS-CoV-2 susceptibility. Viral entry/replication can be studied but the cells may not replicate all aspects of lung infection.
ac. HEK293-ACE2+ is a human embryonic kidney cell line engineered for high ACE2 expression and SARS-CoV-2 susceptibility.
ad. Huh-7 cells were derived from a liver tumor (hepatoma).
ae. Caco-2 cells come from a colorectal adenocarcinoma (cancer). They are valued for their ability to form a polarized cell layer with properties similar to the intestinal lining.
af. Vero E6 is an African green monkey kidney cell line with low/no ACE2 expression and high SARS-CoV-2 susceptibility. The cell line is easy to maintain and supports robust viral replication, however the monkey origin may not accurately represent human responses.
ag. mTEC is a mouse tubular epithelial cell line.
ah. RAW264.7 is a mouse macrophage cell line.
ai. A mouse model expressing the human ACE2 receptor under the control of the K18 promoter.
aj. A mouse model of obesity and severe insulin resistance leading to type 2 diabetes due to a mutation in the leptin receptor gene that impairs satiety signaling.
ak. A mouse model commonly used in infectious disease and cancer research due to higher immune response and susceptibility to infection.
Alanzi et al., 1 Jun 2023, peer-reviewed, 3 authors. Contact: aralonazi@ksu.edu.sa (corresponding author), mohkhalid@ksu.edu.sa (corresponding author).
In Silico studies are an important part of preclinical research, however results may be very different in vivo.
This PaperQuercetinAll
Structure-based virtual identification of natural inhibitors of SARS-CoV-2 and its Delta and Omicron variant proteins
Abdullah R Alanzi, Mohammad K Parvez, Mohammed S Al-Dosari
Future Virology, doi:10.2217/fvl-2022-0184
Aim: Structure-based identification of natural compounds against SARS-CoV-2, Delta and Omicron target proteins. Materials & methods: Several known antiviral natural compounds were subjected to molecular docking and MD simulation against SARS-CoV-2 Mpro, Helicase and Spike, including Delta and Omicron Spikes. Results: Of the docked ligands, 20 selected for each complex exhibited overall good binding affinities (-7.79 to -5.06 kcal/mol) with acceptable physiochemistry following Lipinski's rule. Finally, two best ligands from each complex upon simulation showed structural stability and compactness. Conclusion: Quercetin-3-acetyl-glucoside, Rutin, Kaempferol, Catechin, Orientin, Obetrioside and Neridienone A were identified as potential inhibitors of SARS-CoV-2 Mpro, Helicase and Spike, while Orientin and Obetrioside also showed good binding affinities with Omicron Spike. Catechin and Neridienone A formed stable complexes with Delta Spike. Plain language summary: Mutant strains of SARS-CoV-2 called 'variants of concern' (VOCs) are linked to a good ability to infect, re-infect and spread among people. They are also linked to poor ability to fight the disease and reduced effectiveness of vaccines. Delta and Omicron are important VOCs because they are difficult to control and treat. Specific resistance to some drugs used to treat COVID-19 poses a further challenge. Therefore, discovering natural or plant-derived drugs with no known resistance would be valuable to the treatment of COVID-19. In this study, we screen and identify seven plantderived compounds that may be useful to treating COVID-19 -we identify Quercetin-3-acetyl-glucoside, Rutin, Kaempferol, Catechin, Orientin, Obetrioside and Neridienone A as potential candidates. Orientin, Obetrioside, Catechin and Neridienone A are identified as candidates against Delta and Omicron for the first time.
Financial & competing interests disclosure The authors acknowledge the Researchers Supporting Project (no. RSP2023R379), King Saud University, Riyadh, Saudi Arabia for funding this work. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript.
References
Aa, Rutin as a promising inhibitor of main protease and other protein targets of COVID-19: in silico study, Nat. Prod Commun
Agrawal, Agrawal, Blunden, Rutin: A Potential Antiviral for Repurposing as a SARS-CoV-2 Main Protease (Mpro) Inhibitor, Nat. Prod. Comm
Badshah, Faisal, Muhammad, Poulson, Emwas et al., Antiviral activities of flavonoids, Biomed. Pharmacother, doi:10.1016/j.biopha.2021.111596
Bai, Wang, Zhao, Bioactive pregnanes from Nerium oleander, J. Nat. Prod
Biancatelli, Berrill, Catravas, Marik, Quercetin and vitamin C: an experimental, synergistic therapy for the prevention and treatment of SARS-CoV-2 related disease (COVID-19), Front. Immunol
Campbell, Archer, Schafer, Increased transmissibility and global spread of SARS-CoV-2 variants of concern as at June, Euro. Surveill, doi:10.2807/1560-7917.ES.2021.26.24.2100509
Case, Aktulga, Belfon, Amber 2021: Reference Manual
Case, Cheatham, Darden, The Amber biomolecular simulation programs, J. Comput. Chem
Chandel, Raj, Rathi, In silico identification of potent COVID-19 main protease inhibitors from FDA approved antiviral compounds and active phytochemicals through molecular docking: a drug repurposing approach, doi:10.20944/preprints202003.0349.v1
Chattopadhyay, Sarkar, Chatterjee, Recent advancements for the evaluation of antiviral activities of natural products, N. Biotechnol
Chen, Liu, Guo, Emerging coronaviruses: genome structure, replication, and pathogenesis, J. Med. Virol
Cherrak, Merzouk, Mokhtari-Soulimane, Potential bioactive glycosylated flavonoids as SARS-CoV-2 main protease inhibitors: a molecular docking and simulation studies, PLOS One
Corona, Wycisk, Talarico, Natural compounds inhibit SARS-CoV-2 nsp13 unwinding and ATPase enzyme activities
Da Silva, Barreira, Oliveira, Natural phytochemicals and probiotics as bioactive ingredients for functional foods: extraction, biochemistry and protected-delivery technologies, Trends Food Sci. Tech
Dinda, Dinda, Dinda, Chakraborty, Some natural compounds and their analogues having potent anti-SARS-CoV-2 and anti-proteases activities as lead molecules in drug discovery for COVID-19, Eur. J. Med. Chem. Rep, doi:10.1016/j.ejmcr.2022.100079
Dowran, Damavandi, Azad, Reinfection and reactivation of SARS-CoV-2, Future Virol, doi:10.2217/fvl-2021-0212
Duan, Wu, Chowdhury, A point-charge force field for molecular mechanics simulations of proteins based on condensed-phase quantum mechanical calculations, J. Comput. Chem
Elmezayen, Al-Obaidi, Sahin, Drug repurposing for coronavirus (COVID-19): in silico screening of known drugs against coronavirus 3CL hydrolase and protease enzymes
Friesner, Banks, Murphy, Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy, J. Med. Chem
Grant, Skjaerven, Yao, The Bio3D packages for structural bioinformatics, Prot. Sci
Harvey, Carabelli, Jackson, SARS-CoV-2 variants, Spike mutations and immune escape, Nat. Rev. Microbiol
Hillary, Ceasar, An update on COVID-19: SARS-CoV-2 variants, antiviral drugs, and vaccines, Heliyon
Hirabara, Serdan, Gorjao, SARSCOV-2 variants: differences and potential of immune evasion, Front. Cell. Infect. Microbiol, doi:10.3389/fcimb.2021.781429
Humphrey, Dalke, Schulten, VMD: visual molecular dynamics, J Mol Graph
Huynh, Wang, Luan, Structure-based lead optimization of herbal medicine rutin for inhibiting SARS-CoV-2's main protease, Phys. Chem. Chem. Phys
Infusino, Marazzato, Mancone, Diet supplementation, probiotics, and nutraceuticals in SARS-CoV-2 infection: a scoping review, Nutrients
Khan, Heng, Wang, In silico and in vitro evaluation of kaempferol as a potential inhibitor of the SARS-CoV-2 main protease (3CLpro), Phytother. Res
Kim, Nichols, Wang, Mccammon, Effects of histidine protonation and rotameric states on virtual screening of M. tuberculosis RmlC, J. Comput. Aided Mol. Des
Ligprep, Ligprep, None
Mali, Chaudhari, Computational studies on imidazo [1, 2-a] pyridine-3-carboxamide analogues as antimycobacterial agents: common pharmacophore generation, atom-based 3D-QSAR, molecular dynamics simulation, QikProp, molecular docking and prime MMGBSA approaches, Open Pharm. Sci. J
Mangiavacchi, Botwina, Menichetti, Seleno-functionalization of quercetin improves the non-covalent inhibition of Mpro and its antiviral activity in cells against SARS-CoV-2, Int. J. Mol. Sci
Ohishi, Hishiki, Baig, Epigallocatechin gallate (EGCG) attenuates severe acute respiratory coronavirus disease 2 (SARS-CoV-2) infection by blocking the interaction of SARS-CoV-2 spike protein receptor-binding domain to human angiotensin-converting enzyme 2, PLOS One
Orgensen, Chandrasekhar, Madura, Impey, Klein, Comparison of simple potential functions for simulating liquid water, J. Chem. Phys
Padhan, Parvez, Ms, Comparative sequence analysis of SARS-CoV-2 suggests its high transmissibility and pathogenicity, Future Virol, doi:10.2217/fvl-2020-0204
Pan, Lezama-Davila, Ap, Sterols with antileishmanial activity isolated from the roots of Pentalinon andrieuxii, Phytochemistry
Parvez, Ahmed, Ms, Novel Anti-Hepatitis B Virus Activity of Euphorbia schimperi and Its Quercetin and Kaempferol Derivatives, ACS Omega
Parvez, Al-Dosari, Abdelwahid, Alqahtani, Alanzi, Novel anti-hepatitis B virus-active catechin and epicatechin from Rhus tripartita, Exp. Ther. Med
Parvez, Jagirdar, Purty, COVID-19 pandemic: understanding the emergence, pathogenesis and containment (Review), World Acad. Sci. J
Parvez, Rehman, Alam, Ms, Alqasoumi et al., Plant-derived antiviral drugs as novel hepatitis B virus inhibitors: cell culture and molecular docking study, Saudi Pharm. J
Phillips, Hardy, Maia, Scalable molecular dynamics on CPU and GPU architectures with NAMD, J. Chem. Phys, doi:10.1063/5.0014475
Pierro, Iqtadar, Khan, Potential clinical benefits of quercetin in the early stage of COVID-19: results of a second, pilot, randomized, controlled and open-label clinical trial, Int. J. Gen. Med
Pinzi, Rastelli, Molecular docking: shifting paradigms in drug discovery, Int. J. Mol. Sci
Reiberger, Radilová, Krá Ľ M, Synthesis and In Vitro Evaluation of C-7 and C-8 Luteolin Derivatives as Influenza Endonuclease Inhibitors, Int. J. Mol. Sci
Ren, Wang, Wu, Identification of a novel coronavirus causing severe pneumonia in human: a descriptive study, Chin. Med. J
Runfeng, Yunlong, Jicheng, Lianhuaqingwen exerts anti-viral and anti-inflammatory activity against novel coronavirus (SARS-CoV-2), Pharmacol. Res, doi:10.1016/j.phrs.2020.104761
Sachse, Tenorio, De Castro, Unraveling the antiviral activity of plitidepsin against SARS-CoV-2 by subcellular and morphological analysis, Antiviral Res, doi:10.1016/j.antiviral.2022.105270
Schwarz, Sauter, Wang, Kaempferol derivatives as antiviral drugs against the 3a channel protein of coronavirus, Planta Med
Sharma, Bhardwaj, Singh, Rajendran, Purohit et al., An in-silico evaluation of different bioactive molecules of tea for their inhibition potency against nonstructural protein-15 of SARS-CoV-2, Food Chem, doi:10.1016/j.foodchem.2020.128933
Shivakumar, Harder, Damm, Friesner, Sherman, Improving the prediction of absolute solvation free energies using the next generation OPLS force field, Chem. Theory Comput
Sivakumar, Anuragh, Kammala, Ilango, Computer aided drug design approach to screen phytoconstituents of Adhatoda vasica as potential inhibitors of SARS-CoV-2 Main Protease enzyme, Life (Basel)
Sulaiman, Zarubaev, Samudi, Natural products from medicinal plants in Asia and the Pacific for RNA viruses: hercules' fifth labour, Pharm. Biol
Versiani, Ahmed, Ikram, Ali, Yasmeen et al., Chemical constituents and biological activities of Adenium obesum (Forsk.) Roem. et Schult, Chem. Biodiver
Vrijsen, Everaert, Boeye, Antiviral activity of flavones and potentiation by ascorbate, J. Gen. Virol
Wahab, Aboelmaaty, Lahloub, Sallam, In vitro and in silico studies of SARS-CoV-2 main protease Mpro inhibitors isolated from Helichrysum bracteatum, RSC Adv
Walls, Park, Tortorici, Wall, Mcguire et al., Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein, Cell
Wan, Xiang, Fang, Clinical features and treatment of COVID-19 patients in northeast Chongqing
Wan, Xiang, Fang, Clinical features and treatment of COVID-19 patients in northeast Chongqing, J. Med. Virol
Wang, Wang, Yang, Song, Bioactive natural products in COVID-19 therapy, Front. Pharmacol, doi:10.3389/fphar.2022.926507
Wang, Zhang, Wang, Alterations in microbiota of patients with COVID-19: potential mechanisms and therapeutic interventions, Sig. Transduct. Target Ther
Weinzierl, Molecular dynamics simulations of human FOXO3 reveal intrinsically disordered regions spread spatially by intramolecular electrostatic repulsion, Biomolecules
Wu, Liu, Yang, Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods, Acta Pharm. Sin. B
Yan, Zheng, Zeng, He, Cheng, Structural biology of SARS-CoV-2: open the door for novel therapies, Sig. Transduct. Target Ther
Ziebuhr, Molecular biology of severe acute respiratory syndrome coronavirus, Curr. Opin. Microbiol
{ 'indexed': {'date-parts': [[2023, 6, 2]], 'date-time': '2023-06-02T04:31:05Z', 'timestamp': 1685680265080}, 'reference-count': 66, 'publisher': 'Future Medicine Ltd', 'funder': [{'name': 'Researchers Supporting Project, KSU, Riyadh'}], 'content-domain': {'domain': [], 'crossmark-restriction': False}, 'abstract': '<jats:p> Aim: Structure-based identification of natural compounds against SARS-CoV-2, Delta ' 'and Omicron target proteins. Materials &amp; methods: Several known antiviral natural ' 'compounds were subjected to molecular docking and MD simulation against SARS-CoV-2 Mpro, ' 'Helicase and Spike, including Delta and Omicron Spikes. Results: Of the docked ligands, 20 ' 'selected for each complex exhibited overall good binding affinities (-7.79 to -5.06\xa0' "kcal/mol) with acceptable physiochemistry following Lipinski's rule. Finally, two best " 'ligands from each complex upon simulation showed structural stability and compactness. ' 'Conclusion: Quercetin-3-acetyl-glucoside, Rutin, Kaempferol, Catechin, Orientin, Obetrioside ' 'and Neridienone A were identified as potential inhibitors of SARS-CoV-2 Mpro, Helicase and ' 'Spike, while Orientin and Obetrioside also showed good binding-affinities with Omicron Spike. ' 'Catechin and Neridienone A formed stable complexes with Delta Spike. </jats:p>', 'DOI': '10.2217/fvl-2022-0184', 'type': 'journal-article', 'created': {'date-parts': [[2023, 6, 1]], 'date-time': '2023-06-01T15:01:28Z', 'timestamp': 1685631688000}, 'source': 'Crossref', 'is-referenced-by-count': 0, 'title': 'Structure-based virtual identification of natural inhibitors of SARS-CoV-2 and its Delta and ' 'Omicron variant proteins', 'prefix': '10.2217', 'author': [ { 'given': 'Abdullah R', 'family': 'Alanzi', 'sequence': 'first', 'affiliation': [ { 'name': 'Department of Pharmacognosy, College of Pharmacy, King Saud ' 'University, Riyadh, 11451, Saudi Arabia'}]}, { 'ORCID': 'http://orcid.org/0000-0002-7154-9151', 'authenticated-orcid': False, 'given': 'Mohammad K', 'family': 'Parvez', 'sequence': 'additional', 'affiliation': [ { 'name': 'Department of Pharmacognosy, College of Pharmacy, King Saud ' 'University, Riyadh, 11451, Saudi Arabia'}]}, { 'given': 'Mohammed S', 'family': 'Al-Dosari', 'sequence': 'additional', 'affiliation': [ { 'name': 'Department of Pharmacognosy, College of Pharmacy, King Saud ' 'University, Riyadh, 11451, Saudi Arabia'}]}], 'member': '1057', 'published-online': {'date-parts': [[2023, 6, 1]]}, 'reference': [ {'key': 'B1', 'doi-asserted-by': 'publisher', 'DOI': '10.1097/CM9.0000000000000722'}, { 'key': 'B2', 'unstructured': 'World Health Organization. WHO Coronavirus Disease (COVID-19) Dashboard. ' '(2023). https://covid19.who.int/'}, { 'key': 'B3', 'first-page': '59', 'volume': '2', 'author': 'Parvez MK', 'year': '2020', 'journal-title': 'World Acad. Sci. J.'}, {'key': 'B4', 'doi-asserted-by': 'publisher', 'DOI': '10.1002/jmv.25681'}, {'key': 'B5', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.mib.2004.06.007'}, {'key': 'B6', 'doi-asserted-by': 'publisher', 'DOI': '10.1038/s41392-022-00884-5'}, {'key': 'B7', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.cell.2020.02.058'}, { 'key': 'B8', 'unstructured': 'Centers for Disease Control and Prevention. Emerging SARS-CoV-2 ' 'Variants. (2022). ' 'https://www.cdc.gov/coronavirus/2019-ncov/more/science-and-research/scientific-brief-emerging-variants.html'}, {'key': 'B9', 'doi-asserted-by': 'publisher', 'DOI': '10.2217/fvl-2021-0212'}, {'key': 'B10', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.heliyon.2023.e13952'}, {'key': 'B11', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.nbt.2009.03.007'}, {'key': 'B12', 'doi-asserted-by': 'publisher', 'DOI': '10.1002/jmv.25783'}, { 'key': 'B13', 'volume': '6', 'author': 'Dinda B', 'year': '2022', 'journal-title': 'Eur. J. Med. Chem. Rep.'}, {'key': 'B14', 'author': 'Chandel V', 'year': '2020', 'journal-title': 'Preprints'}, { 'key': 'B15', 'doi-asserted-by': 'crossref', 'first-page': '1', 'DOI': '10.1080/07391102.2019.1580616', 'volume': '38', 'author': 'Elmezayen AD', 'year': '2020', 'journal-title': 'J. Biomol. Struc. Dyn.'}, {'key': 'B16', 'doi-asserted-by': 'publisher', 'DOI': '10.1021/acsptsci.1c00253'}, { 'key': 'B17', 'volume': '13', 'author': 'Wang Z', 'year': '2022', 'journal-title': 'Front. Pharmacol.'}, {'key': 'B18', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.antiviral.2022.105270'}, {'key': 'B19', 'volume-title': 'LigPrep.', 'author': 'LigPrep', 'year': '2018'}, {'key': 'B20', 'doi-asserted-by': 'publisher', 'DOI': '10.1021/ct300203w'}, {'key': 'B21', 'volume-title': 'Schrödinger', 'year': '2017'}, {'key': 'B22', 'doi-asserted-by': 'publisher', 'DOI': '10.1007/s10822-013-9643-9'}, {'key': 'B23', 'doi-asserted-by': 'publisher', 'DOI': '10.1021/jm0306430'}, {'key': 'B24', 'doi-asserted-by': 'publisher', 'DOI': '10.2174/1874844901805010012'}, {'key': 'B25', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/0263-7855(96)00018-5'}, {'key': 'B26', 'doi-asserted-by': 'publisher', 'DOI': '10.1063/5.0014475'}, { 'key': 'B27', 'volume-title': 'Amber 2021: Reference Manual.', 'author': 'Case DA', 'year': '2021'}, {'key': 'B28', 'doi-asserted-by': 'publisher', 'DOI': '10.1002/jcc.20290'}, {'key': 'B29', 'doi-asserted-by': 'publisher', 'DOI': '10.1063/1.445869'}, {'key': 'B30', 'doi-asserted-by': 'publisher', 'DOI': '10.1002/jcc.10349'}, {'key': 'B31', 'doi-asserted-by': 'publisher', 'DOI': '10.1002/pro.3923'}, {'key': 'B32', 'doi-asserted-by': 'publisher', 'DOI': '10.3390/biom11060856'}, {'key': 'B33', 'doi-asserted-by': 'publisher', 'DOI': '10.3390/ijms20184331'}, {'key': 'B34', 'doi-asserted-by': 'publisher', 'DOI': '10.2217/fvl-2020-0204'}, {'key': 'B35', 'doi-asserted-by': 'publisher', 'DOI': '10.1038/s41579-021-00573-0'}, { 'key': 'B36', 'doi-asserted-by': 'publisher', 'DOI': '10.2807/1560-7917.ES.2021.26.24.2100509'}, {'key': 'B37', 'doi-asserted-by': 'publisher', 'DOI': '10.3389/fcimb.2021.781429'}, {'key': 'B38', 'doi-asserted-by': 'publisher', 'DOI': '10.1080/13880209.2022.2130944'}, {'key': 'B39', 'doi-asserted-by': 'publisher', 'DOI': '10.1099/0022-1317-69-7-1749'}, {'key': 'B40', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.jsps.2018.12.008'}, {'key': 'B41', 'doi-asserted-by': 'publisher', 'DOI': '10.1021/acsomega.1c04320'}, {'key': 'B42', 'doi-asserted-by': 'publisher', 'DOI': '10.3389/fimmu.2020.01451'}, {'key': 'B43', 'doi-asserted-by': 'publisher', 'DOI': '10.3390/ijms22137048'}, {'key': 'B44', 'doi-asserted-by': 'publisher', 'DOI': '10.2147/IJGM.S318949'}, {'key': 'B45', 'doi-asserted-by': 'publisher', 'DOI': '10.1002/jmv.25783'}, {'key': 'B46', 'doi-asserted-by': 'publisher', 'DOI': '10.1371/journal.pone.0240653'}, { 'key': 'B47', 'first-page': '1', 'volume': '16', 'author': 'Agrawal PK', 'year': '2021', 'journal-title': 'Nat. Prod. Comm.'}, { 'key': 'B48', 'first-page': '1', 'volume': '15', 'author': 'Al-Zahrani AA', 'year': '2020', 'journal-title': 'Nat. Prod Commun.'}, {'key': 'B49', 'doi-asserted-by': 'publisher', 'DOI': '10.1039/D0CP03867A'}, {'key': 'B50', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.apsb.2020.02.008'}, {'key': 'B51', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.phrs.2020.104761'}, {'key': 'B52', 'doi-asserted-by': 'publisher', 'DOI': '10.1055/s-0033-1360277'}, {'key': 'B53', 'doi-asserted-by': 'publisher', 'DOI': '10.1002/ptr.6998'}, { 'key': 'B54', 'volume': '40', 'author': 'Badshah SL', 'year': '2021', 'journal-title': 'Biomed. Pharmacother.'}, {'key': 'B55', 'doi-asserted-by': 'publisher', 'DOI': '10.3892/etm.2022.11325'}, {'key': 'B56', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.foodchem.2020.128933'}, { 'key': 'B57', 'doi-asserted-by': 'crossref', 'first-page': 'e0271112', 'DOI': '10.1371/journal.pone.0271112', 'volume': '17', 'author': 'Ohishi T', 'year': '2021', 'journal-title': 'PLOS One'}, {'key': 'B58', 'doi-asserted-by': 'publisher', 'DOI': '10.3390/ijms22147735'}, {'key': 'B59', 'doi-asserted-by': 'publisher', 'DOI': '10.1039/D2RA01213H'}, { 'key': 'B60', 'first-page': '315', 'volume': '12', 'author': 'SivaKumar B', 'year': '2021', 'journal-title': 'Life (Basel).'}, {'key': 'B61', 'doi-asserted-by': 'publisher', 'DOI': '10.1002/cbdv.201200254'}, {'key': 'B62', 'doi-asserted-by': 'publisher', 'DOI': '10.1021/np068030o'}, {'key': 'B63', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.phytochem.2012.06.012'}, {'key': 'B64', 'doi-asserted-by': 'publisher', 'DOI': '10.1038/s41392-022-00986-0'}, { 'key': 'B65', 'first-page': '114', 'volume': '50', 'author': 'da Silva BV', 'year': '2016', 'journal-title': 'Trends Food Sci. Tech.'}, {'key': 'B66', 'doi-asserted-by': 'publisher', 'DOI': '10.3390/nu12061718'}], 'container-title': 'Future Virology', 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://www.futuremedicine.com/doi/pdf/10.2217/fvl-2022-0184', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2023, 6, 1]], 'date-time': '2023-06-01T15:01:46Z', 'timestamp': 1685631706000}, 'score': 1, 'resource': {'primary': {'URL': 'https://www.futuremedicine.com/doi/10.2217/fvl-2022-0184'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2023, 6, 1]]}, 'references-count': 66, 'alternative-id': ['10.2217/fvl-2022-0184'], 'URL': 'http://dx.doi.org/10.2217/fvl-2022-0184', 'relation': {}, 'ISSN': ['1746-0794', '1746-0808'], 'subject': ['Virology'], 'container-title-short': 'Future Virology', 'published': {'date-parts': [[2023, 6, 1]]}}
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit